Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/07/2002WO2002087517A2 Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis or treatment of sensitive skin
11/07/2002WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002WO2002087512A2 Once-a-day oxycodone formulations
11/07/2002WO2002087510A2 Subcellular targeting of therapeutic proteins
11/07/2002WO2002087509A2 Colloidal metal compositions and methods
11/07/2002WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002WO2002087503A2 Compositions and methods for treating colorectal polyps and cancer
11/07/2002WO2002087472A1 Stent-based delivery of statins to prevent restenosis
11/07/2002WO2002087465A2 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002WO2002087423A2 Carbonic anhydrase activators for enhancing learning and memory
11/07/2002WO2002087338A1 Liquid formulations for dermal application in treatment of parasitic insects in animals
11/07/2002WO2002087335A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
11/07/2002WO2002070537A3 Fusidic acid derivatives
11/07/2002WO2002069956A3 Use of carnitine for increasing testosteron
11/07/2002WO2002069892A3 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
11/07/2002WO2002068614A3 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
11/07/2002WO2002067955A3 A process for the manufacture of a herbal composition comprising a matrine
11/07/2002WO2002066026A3 Tramadol-based medicament
11/07/2002WO2002065993A3 Use of aryl nitrone compounds in methods for treating neuropathic pain
11/07/2002WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002WO2002056913A3 Stabilized brivudine topical formulations containing metal oxide pigments
11/07/2002WO2002056872A3 Antiproliferative colchicine compositions and uses thereof
11/07/2002WO2002056827A3 Substituted felbamate derived compounds
11/07/2002WO2002056708A3 Preparation for improved dietary utilisation
11/07/2002WO2002051421A3 Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
11/07/2002WO2002050084A3 Streptogramin derivatives preparation thereof and compositions containing same
11/07/2002WO2002047693A3 Steroid hormone products comprising a stabilizing agent in non-crystalline form
11/07/2002WO2002045681A3 Solid polyunsaturated fatty acid compositions
11/07/2002WO2002044141A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
11/07/2002WO2002043655A3 Inhibition of exoprotein production from grampositive bacteria
11/07/2002WO2002043580A3 Production of microspheres
11/07/2002WO2002040030A8 Combination therapy for lowering and controlling intraocular pressure
11/07/2002WO2002040001A3 Compositions for treatment of malignant effusions comprising a biocompatible polymer and antineoplastic taxane
11/07/2002WO2002028897A3 Human g-protein coupled receptor and uses thereof
11/07/2002WO2002028424A3 Kyberdrug as autovaccines with immune-regulating effects
11/07/2002WO2002024930A3 Artificial ubiquitous chromatin opening elements (ucoe)
11/07/2002WO2002024203A3 Controlled release formulations for oral administration
11/07/2002WO2002009767A3 Therapeutic polyanhydride compounds for drug delivery
11/07/2002WO2002009667A3 Dispersions for formulating slightly or poorly soluble active ingredients
11/07/2002WO2002007732A3 Use of panaxatriol for stimulation angiogenesis
11/07/2002WO2001091765A3 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
11/07/2002WO2001086002A9 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/07/2002WO2001085687A1 Substituted indoles as parp inhibitors
11/07/2002WO2001047866A9 Substituted 1 and 2 naphthol mannich bases
11/07/2002WO2001046408A9 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
11/07/2002WO2001036365A3 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
11/07/2002WO2001034586A3 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
11/07/2002WO2001027305A9 Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms
11/07/2002WO2001021220A9 Bioprosthetic heart valves
11/07/2002WO2001015745A9 Method and formula for tumor remission and suppression of cancer
11/07/2002WO2000064420A3 Compositions and methods for treating amyloidosis using sulphonate derivatives
11/07/2002US20020166145 Coffee mannanase
11/07/2002US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002US20020165617 Phospholipid-coated implants
11/07/2002US20020165608 Local drug delivery devices and methods for maintaining the drug coatings thereon
11/07/2002US20020165429 Clitoral sensitizing arrangements
11/07/2002US20020165412 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
11/07/2002US20020165406 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
11/07/2002US20020165402 Quarternary ammonium compounds
11/07/2002US20020165400 Antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex; thrombolytic agents
11/07/2002US20020165399 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
11/07/2002US20020165395 Substituted piperidine derivatives
11/07/2002US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002US20020165377 ADAM polynucleotides, polypeptides, and antibodies
11/07/2002US20020165374 Secreted protein HFEAF41
11/07/2002US20020165373 Contacting the sample with an isolated recombinant immunodominant Neospora antigen, forming an antigen/antibody complex, and detecting the presence or absence of the complex
11/07/2002US20020165365 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
11/07/2002US20020165361 Antibody for use in the diagnosis and treatment of cell proliferation disorders
11/07/2002US20020165343 Growth hormone secretagogues
11/07/2002US20020165285 Production of dry powders of one or more oxygenated carotenoids
11/07/2002US20020165284 Both the R and S enantiomers free of each other; treating depression
11/07/2002US20020165282 PPAR agonists
11/07/2002US20020165281 Can reverse damages caused by anoxic encephalopathy and ischemic events
11/07/2002US20020165280 Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein UCP2
11/07/2002US20020165279 Methods for preventing lesions caused by viruses of the herpesviridae or poxviridae family
11/07/2002US20020165278 Contacting with a C1 to C3 monohydroxy alcohol or C3 to C4 diol and a sufficient amount of an acid to adjust the pH to below 4.6; treating lesions associated with herpes infections
11/07/2002US20020165277 Virucidal compositions
11/07/2002US20020165276 Method for preventing and treating inflammatory somatic pain and chronic pain
11/07/2002US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002US20020165274 Use of aryl nitrone compounds in methods for treating neuropathic pain
11/07/2002US20020165273 Carbamate compounds for use in preventing or treating neurodegenerative disorders
11/07/2002US20020165272 Carbamate compounds for use in preventing or treating psychotic disorders
11/07/2002US20020165271 Topical composition where vitamin C made by contacting an ascorbic acid precursor with the exception of its esters with an enzyme; L-galactono-1,4-lactone converted with L-galactono-1,4-lactone dehydrogenase; stability
11/07/2002US20020165270 Administering bilobalide
11/07/2002US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002US20020165267 Phloxin B a color additive in cosmetics and food use thereof as anti-microbial agent.
11/07/2002US20020165266 Such as skin grafts
11/07/2002US20020165265 Microtubule disrupter such as paclitaxel, and a polymeric carrier that is NOT a capsule; embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions
11/07/2002US20020165263 Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors
11/07/2002US20020165262 Methods and products relating to 16-HETE analogs
11/07/2002US20020165261 Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
11/07/2002US20020165260 Compositions and methods for the treatment and prevention of bovine mastitis
11/07/2002US20020165258 For tumors that have initially been unresponsive to taxane therapy and developed drug resistance
11/07/2002US20020165257 For patients exhibiting resistance to oncology and chemotherapy with taxanes; antiproliferative agents
11/07/2002US20020165256 Fermentative preparation process for and crystal forms of cytostatics
11/07/2002US20020165255 Prostaglandin agonists such as (3-(methanesulfonylamino-methyl)-phenoxy)-acetic acid methyl ester for preventing/ restoring bone mass loss
11/07/2002US20020165254 Autoclavable pharmaceutical compositions containing a chelating agent
11/07/2002US20020165253 Such as N-(4-chlorobenzyl)-8-(4-hydroxybut-1-ynyl)-1-methyl-6-(morpholin-4-ylmethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide for treatment against herpes viruse; enzyme inhibitors
11/07/2002US20020165252 Such as methyl-2-cyclopentyl-4-(4-fluorophenyl)-5-oxo-7,7-dimethyl-1,4,5,6,7,8 -hexahydroquinoline-3-carboxylate for treatment of arteriosclerosis and dyslipidaemias; condensation
11/07/2002US20020165249 Nasal delivery of apomorphine
1 ... 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 ... 7860